AU2017247006B2 - Radiotherapy improvements - Google Patents

Radiotherapy improvements Download PDF

Info

Publication number
AU2017247006B2
AU2017247006B2 AU2017247006A AU2017247006A AU2017247006B2 AU 2017247006 B2 AU2017247006 B2 AU 2017247006B2 AU 2017247006 A AU2017247006 A AU 2017247006A AU 2017247006 A AU2017247006 A AU 2017247006A AU 2017247006 B2 AU2017247006 B2 AU 2017247006B2
Authority
AU
Australia
Prior art keywords
individual
tumours
irradiated
radiotherapy
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017247006A
Other languages
English (en)
Other versions
AU2017247006A1 (en
Inventor
Graham Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noxopharm Ltd
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2016/050674 external-priority patent/WO2017173474A1/en
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of AU2017247006A1 publication Critical patent/AU2017247006A1/en
Application granted granted Critical
Publication of AU2017247006B2 publication Critical patent/AU2017247006B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017247006A 2016-04-06 2017-04-06 Radiotherapy improvements Ceased AU2017247006B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
AUPCT/AU2016/050674 2016-07-28
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment
US201762461559P 2017-02-21 2017-02-21
US62/461,559 2017-02-21
PCT/AU2017/050299 WO2017173496A1 (en) 2016-04-06 2017-04-06 Radiotherapy improvements

Publications (2)

Publication Number Publication Date
AU2017247006A1 AU2017247006A1 (en) 2018-11-01
AU2017247006B2 true AU2017247006B2 (en) 2022-05-12

Family

ID=60000154

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017247006A Ceased AU2017247006B2 (en) 2016-04-06 2017-04-06 Radiotherapy improvements

Country Status (6)

Country Link
US (2) US11229703B2 (cg-RX-API-DMAC10.html)
EP (1) EP3439642A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019513826A (cg-RX-API-DMAC10.html)
AU (1) AU2017247006B2 (cg-RX-API-DMAC10.html)
CA (1) CA3058492A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017173496A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049008A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
WO2015069562A1 (en) * 2013-11-07 2015-05-14 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
EP1503751A4 (en) 2002-04-09 2007-08-01 Novogen Res Pty Ltd THERAPEUTIC PROCESSES AND COMPOSITIONS WITH ISOFLAV-3-EN AND ISOFLAVAN STRUCTURES
AU2003259220C1 (en) 2002-07-24 2017-08-24 Australian Health & Nutrition Association Limited Compositions and products containing enantiomeric equol, and methods for their making
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
AU2004273910A1 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050154452A1 (en) 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7434690B2 (en) 2004-04-30 2008-10-14 Cutispharma, Inc. Container and method for the preparation, storage and dispensing of compounded suppositories
US8080675B2 (en) * 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
CN101056868B (zh) * 2004-09-21 2012-05-02 马休爱德华兹股份有限公司 取代的苯并二氢吡喃衍生物、药物及其在治疗中的应用
DE102005009515A1 (de) 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
AU2006227555A1 (en) 2005-03-24 2006-09-28 Novogen Research Pty Ltd Isoflavonoid dimers
AU2006292507A1 (en) 2005-09-15 2007-03-29 Umd, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
US20070196381A1 (en) 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
CA2668008A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
JP2010531811A (ja) 2007-06-29 2010-09-30 ノボゲン リサーチ ピーティーワイ リミテッド ２−置換イソフラボノイド化合物、医薬及び使用
CA2738328A1 (en) 2008-08-29 2010-03-04 Novogen Research Pty Ltd Immunomodulating activities
WO2010054438A1 (en) 2008-11-14 2010-05-20 Heartlink Ltd Aryl di-substituted propenone compounds
KR20110004525A (ko) 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
CA2852066A1 (en) * 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
PL2968294T3 (pl) * 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
ES2643407T3 (es) * 2014-02-07 2017-11-22 Novogen Ltd. Compuestos de benzopirano funcionalizados y uso de los mismos
WO2017025918A1 (en) 2015-08-11 2017-02-16 Novartis Ag 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
US20190038713A1 (en) * 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
US20190160004A1 (en) * 2016-04-06 2019-05-30 Noxopharm Limited Improvements in cancer treatment
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
AU2017254774B2 (en) 2016-04-22 2021-10-21 Noxopharm Limited Chemotherapy improvements
AU2019285640A1 (en) 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
US20190380998A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2020051644A1 (en) 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049008A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
WO2015069562A1 (en) * 2013-11-07 2015-05-14 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Phase I Study of Idronoxil Combined With Radiation Treatment in Men With Metastatic Prostate Cancer", ClinicalTrials.gov archive [online], NCT03041285 on 1 February 2017, URL: https://clinicaltrials.gov/archive/NCT03041285/2017_02_01, *
GRUCA et al., "Synthetic Genistein Glycosides Inhibiting EGFR phosphorylation Enhance the Effect of Radiation in HCT 116 Colon Cancer Cells", Molecules, (2014), vol. 19, no. 11, pages 18558 - 18573 *
KIM et al., "Genistein decreases cellular redox potential, partially supresses cell growth in HL-60 leukemia cells and sensitizes cells to γ-irradiation-induced cell death", Molecular Medicine Reports, (2014), vol. 10, no. 6, pp. 2786-2792 *
LUDGATE, "Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPS, and DAMPs", Clinical Cancer Research, (2012), vol. 18, no. 17, pages 4522 - 4525 *
RAFFOUL et al., "Radiosensitization of prostate cancer by soy isoflavones", Current Cancer Drug Targets, (2007-12-01), vol. 7, no. 8, doi:10.2174/156800907783220408, ISSN 1568-0096, pages 759 - 765 *
SHIN et al., "Sensitization of the Apoptotic Effect of y-Irradiation in Genistein- pretreated CaSki Cervical Cancer Cells", Journal of Microbiology & Biotechnology, (2008), vol. 18, no. 3, pages 523 - 531 *

Also Published As

Publication number Publication date
WO2017173496A1 (en) 2017-10-12
US20190262451A1 (en) 2019-08-29
US11229703B2 (en) 2022-01-25
CA3058492A1 (en) 2017-10-12
JP2019513826A (ja) 2019-05-30
US20220105182A1 (en) 2022-04-07
EP3439642A1 (en) 2019-02-13
AU2017247006A1 (en) 2018-11-01
EP3439642A4 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
Vacchelli et al. Trial Watch: Chemotherapy with immunogenic cell death inducers
JP6787792B2 (ja) がんの処置のための併用治療
JP7772748B2 (ja) 治療用ナノ生物学的組成物による訓練免疫の促進
JP7490361B2 (ja) ｉｎ ｓｉｔｕ免疫調節癌ワクチン接種のための放射性ハロゲン化剤
EP4461372A2 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
JP7627259B2 (ja) 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ）
Rini Future approaches in immunotherapy
CN109069512A (zh) 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
Velenik et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer
Weber Current perspectives on immunotherapy
US20220105182A1 (en) Radiotherapy improvements
Mouli et al. TIPS-17 a first-in-human feasibility study to evaluate the safety of selective intra-arterial yttrium-90 microsphere treatment in patients with recurrent glioblastoma (the Frontier trial)
Peng et al. Tumor therapeutic modes
Bajek et al. Medical Physics: Models and Technologies in Cancer Research
Navarro et al. American Association for Cancer Research (AACR)-106th Annual Meeting. Philadelphia, Pennsylvania, USA-April 18-22, 2015
Massumoto et al. Complete remission of mantle-cell non-Hodgkin lymphoma with a dendritic cell vaccine
Rüttinger et al. Current immunotherapeutic strategies in lung cancer
Chaturvedi et al. Immunotherapy for breast cancer
WO2024236048A1 (en) Combination therapy for treating tumors with radiotherapy
Klautke et al. PD (L) 1-Inhibitors and Radiation: A Good Combination for Local and Systemic Effects?
Chan Understanding cancer therapies
Vodeneev et al. Targeted radionuclide therapy: current status and prospects
Koontz et al. Principles of radiation oncology
Ezziddin et al. Correspondence (letter to the editor): Radioembolization as a Treatment Option
Tsamaloukas Correspondence (letter to the editor): Isocitrate Dehydrogenase Genes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired